Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Could Sponsors’ Supply Chain Policing Have Caught Alleged CRO Fraud?

Executive Summary

The US FDA always encourages sponsors to ensure their suppliers and contractors are following the law, but agency inspectors may have been the only ones who could have discovered the data integrity problems that forced the downgrading of more than 100 generic drug applications.

You may also be interested in...



Final PIC/S Data Integrity Guidance Encourages Foolproof Approaches To Drug Manufacturing Data

Association of inspectorates provides most detailed blueprint yet of how to assure pharmaceutical data integrity.

US FDA Says Data Integrity Remains Challenging For API Manufacturers

Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.

Full US FDA Independent Review Of Janssen Booster Data May Not Continue Post-EUA

The agency said its booster EUA decision was based on the immunogenicity studies that were submitted.

Topics

UsernamePublicRestriction

Register

PS145068

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel